Abstract 807P
Background
Ovarian cancer (OC) is the most lethal gynecologic tumor and is characterized by a widespread metastasis in abdominal cavity. Accurate preoperative evaluation is important for the specification of surgical procedures and prediction of surgical outcomes.Currently, a variety of imaging techniques can be used for preoperative evaluation of ovarian cancer such as the Computed Tomography (CT) Suidan score. However, the Magnetic resonance imaging (MRI) based preoperative evaluation was not fully explored. Here, our study explores the feasibility of MRI as a preoperative assessment in OC patients.
Methods
This is a prospective, non-randomized, single-center trial of 134 epithelial ovarian cancer (EOC) patients treated with surgical cytoreduction between 2018 and 2022. All patients underwent preoperative MRI scan. The imaging score consists of lesion size scores in 33 areas of the abdominal cavity.
Results
Complete cytoreduction (CC) was achieved in 81 (60.4%) of 134 patients. CC patients with a median MRI score of 10(4 - 44) and the median MRI score of patients who were incompletely cytoreduced (IC) was 15(5 - 48). By comparing imaging scores with those seen in surgery, we found that MRI evaluation is in good agreement with intraoperative observation. However, for areas such as the small bowel mesentery, the MRI score is lower than the intraoperative score, while for lymph node metastases the MRI score is higher than the intraoperative score. Through multi-factor analysis, we have screened clinical and imaging criteria related to IC including CA125 level, prognostic nutritional index (PNI), diaphragmatic surface of spleen lesion, gallbladder fossa lesion and small bowel mesentery lesion. Based on these criteria, we have constructed preoperative imaging scores and the ‘predictive score’ was assigned to each criterion based on its multivariate OR.
Conclusions
Our research explores the feasibility of incorporating tumor load into MRI based preoperative assessment for OC patients. Also, we identified 5 criteria associated with IC, and developed a predictive model which may be helpful in treatment planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11